News of Note—Roche's blockbuster licensing deal; FibroGen's roxadustat application and more
admin 23rd December 2019 Uncategorised 0As we highlight some of our top special reports this year, here’s news we didn’t want readers to miss. In the day’s biggest development, Roche picked up ex-U.S. rights to Sarepta’s Duchenne muscular dystrophy gene therapy for more than $1
read more